Citation Impact
Citing Papers
In vivo imaging of hydrogen peroxide production in a murine tumor model with a chemoselective bioluminescent reporter
2010 StandoutNobel
A hexahistidine-Zn 2+ -dye label reveals STIM1 surface exposure
2007 StandoutNobel
Untangling the ErbB signalling network
2001 Standout
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
1999
A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours
2002
HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer
1997
Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains
1991 StandoutNobel
By-passing immunization
1991 StandoutNobel
Inference of Macromolecular Assemblies from Crystalline State
2007 Standout
The Role of β-Glucuronidase in Drug Disposition and Drug Targeting in Humans
1997
Dominance of intrinsic genetic factors in shaping the human immunoglobulin Vλ repertoire
1999 StandoutNobel
Resumption of high‐dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients
2012
Dissemination and growth of cancer cells in metastatic sites
2002 Standout
Man-made antibodies
1991 NatureNobel
Effect of pegylation on pharmaceuticals
2003 Standout
Selective activation of anticancer prodrugs by monoclonal antibody–enzyme conjugates
2001
Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain
1996 StandoutNobel
Bacterial protease inhibitors
2002
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Single‐Triggered Trimeric Prodrugs
2005
Novel growth regulatory factors and tumour angiogenesis
1991
Crystal structure of carboxypeptidase G2, a bacterial enzyme with applications in cancer therapy
1997
Improved biochemical strategies for targeted delivery of taxoids
2007
Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity
2009 Standout
Exploiting tumour hypoxia in cancer treatment
2004 Standout
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
2001 Standout
The Role of c-erbB-2/HER2/neu in Breast Cancer Progression and Metastasis
2001
By-passing immunisation
1992 StandoutNobel
Polyphenols: food sources and bioavailability
2004 Standout
Natural Product Hybrids as New Leads for Drug Discovery
2003 Standout
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
By–Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling
1992 StandoutNobel
Recent developments in the field of antitumour anthracyclines
2001
Human Antibody Fragments Specific for Human Blood Group Antigens from a Phage Display Library
1993 StandoutNobel
Selection of phage antibodies by binding affinity
1992 StandoutNobel
The repertoire of human germline vH sequences reveals about fifty groups of VH segments with different hypervariable loops
1992 StandoutNobel
Tumor-activated Prodrugs—A New Approach to Cancer Therapy
2004
Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo
1992
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Bringing chemistry to life
2011 StandoutNobel
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
2000 Standout
The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)
1993
Designing dendrimers for biological applications
2005 Standout
Making antibody fragments using phage display libraries
1991 StandoutNatureNobel
Open sandwich ELISA: A novel immunoassay based on the interchain interaction of antibody variable region
1996 StandoutNobel
Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)
2004
Computational design of ligand-binding proteins with high affinity and selectivity
2013 StandoutNatureNobel
Synthetic human antibodies and a strategy for protein engineering
1998 StandoutNobel
In-cell PCR from mRNA: amplifying and linking the rearranged immunoglobulin heavy and light chain V-genes within single cells
1992 StandoutNobel
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
A strategy for the isolation of catalytic activities from repertoires of enzymes displayed on phage 1 1Edited by J. Karn
1999 StandoutNobel
Glucarpidase, Leucovorin, and Thymidine for High-Dose Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic Factors Affecting Outcome
2010
Targeted Protein Functionalization Using His-Tags
2004
Suspected Methotrexate Toxicity From Omeprazole
2012
Glucarpidase (Carboxypeptidase G2) Intervention in Adult and Elderly Cancer Patients with Renal Dysfunction and Delayed Methotrexate Elimination After High-Dose Methotrexate Therapy
2007
Polymeric nanovehicles for anticancer drugs with triggering release mechanisms
2007
Ligand-Binding Proteins: Their Potential for Application in Systems for Controlled Delivery and Uptake of Ligands
2000
Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents.
1994 StandoutNobel
Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs
2008
Fluorescence Lifetime Measurements and Biological Imaging
2010 Standout
Efficacy of Glucarpidase (Carboxypeptidase G 2) in Patients with Acute Kidney Injury After High‐Dose Methotrexate Therapy
2013
Prodrugs of Anthracyclines for Use in Antibody-Directed Enzyme Prodrug Therapy
1998
Accelerated Clearance of Polyethylene Glycol-Modified Proteins by Anti-Polyethylene Glycol IgM
1999
Making Antibodies by Phage Display Technology
1994 StandoutNobel
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
Bacterial proteases: current therapeutic use and future prospects for the development of new antibiotics
2001
Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial
1997
Synthesis of an organoinsulin molecule that can be activated by antibody catalysis
2001 StandoutNobel
"Diabodies": small bivalent and bispecific antibody fragments.
1993 StandoutNobel
Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies.
1991
Enzyme-Responsive Snap-Top Covered Silica Nanocontainers
2008 StandoutNobel
Sustained Tumor Regression of Human Colorectal Cancer Xenografts Using a Multifunctional Mannosylated Fusion Protein in Antibody-Directed Enzyme Prodrug Therapy
2005
Fluorescent Chemosensors Based on Spiroring-Opening of Xanthenes and Related Derivatives
2011 Standout
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Antibody–Enzyme Fusion Proteins for Cancer Therapy
2011
Understanding and Managing Methotrexate Nephrotoxicity
2006
Antibody Fragments in Tumor Pretargeting. Evaluation of Biotinylated Fab‘ Colocalization with Recombinant Streptavidin and Avidin
1996
Time-dependent whole-body fluorescence tomography of probe bio-distributions in mice
2005
Single‐Triggered Trimeric Prodrugs
2005
Antibody-directed enzyme prodrug therapy (ADEPT): a review
1997
Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs.
1995
Multiple event activation of a generic prodrug trigger by antibody catalysis
1999 StandoutNobel
Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing.
1996
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
1994 StandoutScience
Second-Generation Difluorinated Cyclooctynes for Copper-Free Click Chemistry
2008 StandoutNobel
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
2002 Standout
Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system.
1992 StandoutNobel
Discovery and Development of Antineoplastic Agents from Natural Sources
1989
Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?
2012 Standout
Preventing and Managing Toxicities of High-Dose Methotrexate
2016 Standout
Works of RG Melton being referenced
Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.
1994
Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice
1990
Antibody-Enzyme Conjugates for Cancer Therapy
1996
Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure
2005
The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model
1990
Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody
1995
A cytotoxic agent can be generated selectively at cancer sites
1988
Optimization of Alkylating Agent Prodrugs Derived from Phenol and Aniline Mustards: A New Clinical Candidate Prodrug (ZD2767) for Antibody-Directed Enzyme Prodrug Therapy
1995
A new clinical candidate for antibody-directed enzyme prodrug therapy (ADEPT): ZD2767
1995
ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.
1996
Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease
1995
ChemInform Abstract: Optimization of Alkylating Agent Prodrugs Derived from Phenol and Aniline Mustards: A New Clinical Candidate Prodrug (ZD2767) for Antibody‐Directed Enzyme Prodrug Therapy (ADEPT).
1996